Kết quả điều trị bước 1 bệnh ung thư biểu mô tế bào gan bằng thuốc lenvatinib=Treatment outcome of using lenvatinib as the first-line regimen for hepatocellular carcinoma patients

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Quyên Mạc, Huy Thành Nguyễn, Mai Lan Nguyễn, Thị Dùng Nguyễn, Thu Hiền Trương

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.202-210

Bộ sưu tập: Metadata

ID: 478141

Thêm vào giỏ

Đánh giá kết quả điều trị bước 1 bệnh ung thư biểu mô tế bào gan (UTBMTBG) bằng thuốc Lenvatinib và nhận xét một số tác dụng không mong muốn của thuốc trong nhóm bệnh nhân nghiên cứu. Đối tượng và phương pháp: Nghiên cứu hồi cứu kết hợp tiến cứu trên bệnh nhân UTBMTBG không có chỉ định phẫu thuật, can thiệp tại chỗ hoặc thất bại với các phương pháp điều trị này tại bệnh viện Ung Bướu Hà Nội từ 07/2020 – 12/2023. Bệnh nhân được điều trị Lenvatinib liều 8-12mg/ngày tùy theo cân nặng cho đến khi bệnh tiến triển, chuyển điều trị chăm sóc giảm nhẹ hoặc độc tính không chấp nhận được. Kết quả: 57 bệnh nhân đủ điều kiện tham gia nghiên cứu. Tỷ lệ kiểm soát bệnh đạt 63,2%, trong đó 8 (14,1%) bệnh nhân có đáp ứng 1 phần, 28 (49,1%) bệnh nhân đạt bệnh giữ nguyên. Trung vị thời gian sống thêm bệnh không tiến triển – PFS là 5,0 tháng. Tỷ lệ sống thêm bệnh không tiến triển tại 3 tháng, 6 tháng, 1 năm lần lượt là 74,9%
39,7% và 6,8%. Trung vị thời gian sống thêm toàn bộ - OS là 9,3 tháng. Có sự khác biệt về OS có ý nghĩa thống kê về chỉ số toàn trạng và phân độ xơ gan theo thang điểm Child-Pugh (p<
0,01). Tác dụng không mong muốn (TDKMM) đa số ở độ 1 và 2, trong đó mệt mỏi và hội chứng bàn tay chân hay gặp nhất lần lượt là 12 (21%) bệnh nhân và 14 (24,6%) bệnh nhân. Kết luận: Lenvatinib là thuốc khá an toàn và hiệu quả trong điều trị bước 1 UTBMTBG.To evaluate the treatment outcome and adverse events of Lenvatinib as the first-line regimen for hepatocellular carcinoma (HCC) patients. Subjects and methods: Retrospective combined prospective study on HCC patients who had neither surgical indication, nor local therapy or who had disease progression after those methods at Hanoi Oncology Hospital from July 2020 to December 2023. Patients received Lenvatinib 8-12mg/day based on body weight until they had disease progression or unacceptable toxicity. Results: Totally 57 eligible patients were enrolled. The disease control rate was 63.2%, of which 8 (14.1%) patients had a partial response, and 28 (49.1%) patients had stable disease. The median progression-free survival (PFS) was 5.0 months. The PFS rates at 3 months, 6 months, and 1 year were 74.9%, 39.7%, and 6.8%, respectively. The median overall survival (OS) was 9.3 months. There was a statistically significant difference in OS in terms of performance status and cirrhosis grading according to the Child-Pugh scale (p<
0.01). Adverse events were mostly at grade 1 and 2, of which fatigue and hand-foot syndrome were the most common, occurring in 12 (21%) and 14 (24.6%) patients, respectively. Conclusion: Lenvatinib appeared to be relatively safe and effective as the first-line treatment for HCC patients.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR